Investigational drug · Phase 3
RGN-259
Also called: Tβ4, Thymosin Beta 4, Timbetasin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neurotrophic Keratopathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
8
Any phase or sponsor naming "RGN-259"
First trial start
2023
Apr 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RGN-259", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neurotrophic Keratopathy
Largest trials
Live from ClinicalTrials.gov: studies naming "RGN-259" as an intervention, largest first.
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3Pivotal-lookingCompleted
ReGenTree, LLCIndustry
NCT03937882 · 700 participants · Start May 24, 2019 · Primary completion Nov 8, 2020
Drug: RGN-259; Placebo · For: Dry Eye Syndromes; Dry Eye
Sites: Phoenix, Arizona; Newport Beach, California; Colorado Springs, Colorado · 20 sites in all
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2Pivotal-lookingCompleted
ReGenTree, LLCIndustry
NCT02974907 · 601 participants · Start Nov 2016 · Primary completion Sep 2017
Drug: RGN-259; Placebo · For: Dry Eye Syndrome
Sites: Phoenix, Arizona; Newport Beach, California; Colorado Springs, Colorado · 10 sites in all
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1Pivotal-lookingCompleted
ReGenTree, LLCIndustry
NCT02597803 · 317 participants · Start Sep 2015 · Primary completion Jun 2016
Drug: RGN-259; Placebo · For: Dry Eye Syndrome
Sites: Andover, Massachusetts
ReGenTree, LLCIndustry
NCT01387347 · 72 participants · Start Aug 2011 · Primary completion Oct 2011
Drug: Thymosin beta 4; Placebo · For: Dry Eye Syndrome; Dry Eye
- Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2Pivotal-lookingCompleted
ReGenTree, LLCIndustry
NCT05555589 · 70 participants · Start Apr 11, 2023 · Primary completion Jul 28, 2026
Drug: RGN-259; Placebo · For: Neurotrophic Keratopathy
Sites: Vestavia Hills, Alabama; Laguna Hills, California; Loma Linda, California · 50 sites in all
- Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1Pivotal-lookingTerminated
ReGenTree, LLCIndustry
NCT02600429 · 18 participants · Start Sep 17, 2015 · Primary completion Nov 20, 2019
Drug: RGN-259; Placebo · For: Neurotrophic Keratopathy
Sites: Lancaster, California; Colorado Springs, Colorado; Fort Collins, Colorado · 11 sites in all
ReGenTree, LLCIndustry
NCT00598871 · 12 participants · Start Dec 2007 · Primary completion Feb 2009
Drug: Thymosin Beta 4 (Tβ4) · For: Diabetes
Sites: Inglewood, California; Los Angeles, California; Orlando, Florida · 5 sites in all
- Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry EyeCompleted
Michigan Cornea Consultants, PCAcademic, hospital or other
NCT01393132 · 9 participants · Start Mar 2011 · Primary completion Dec 2012
Drug: Thymosin Beta 4 eye drops; Vehicle Control · For: Dry Eye; Sjogren's Syndrome; Graft vs. Host Disease
Sites: Southfield, Michigan
Newest research
PubMed records naming it or its code names, newest first.
- Thymosin β4 Mitigates Acute Cerebral Infarction Via Inhibition of the TLR4/NF-κB Pathway and Suppression of Neuronal Pyroptosis.
Zhang Z, Huang Y, Huang S, et al. · Appl Biochem Biotechnol 2026
- Thymosin β4 increases hepatic susceptibility to repeated irradiation and enhances cellular senescence and fibrosis.
Jeong H, Han J, Kim J, et al. · BMB Rep 2026
- Sprayable bioadhesive microcarriers loaded with Tβ4-Engineered ADSC exosomes for diabetic wound healing.
Ding Y, Huang D, Zhao Z, et al. · Bioact Mater 2026
- Adjunctive recombinant human thymosin β4 therapy improves antibacterial outcomes against Staphylococcus aureus.
Banga L, Patel D, Shawky M, et al. · Microbiol Spectr 2026
- Regenerative peptides for inferior alveolar nerve injury: a narrative review.
Froum S, Estrin N, Pico G, et al. · Front Dent Med 2026
- Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500.
Tham A, Hodgkins CW, Kennedy JG · J Am Acad Orthop Surg 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.